Company / Shareholders' Equity
Myriad Genetics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$368.0M
FY2025
5-year range
$368.0M / $967.8M
FY2021-FY2025
Trend
-47.5%
vs FY2024
Sector context
#114 of 213
Health Care
What the data says
At $368M, Myriad Genetics, Inc.'s shareholders' equity ranks #114 of 213 in the Health Care sector. Shareholders' Equity has declined for 4 consecutive years, from $968M in FY2021 to $368M in FY2025.
Based on SEC 10-K filings.
$368M in FY2025 with a 5-year CAGR of -16.0%.
Declined from $783M to $368M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -25.4%
- 5-Year CAGR
- -16.0%
- 10-Year CAGR
- -
Sector benchmark
#114 of 213 in Health CareTop 54% of 213This company $368.0M Sector average $2.5B
▼
-85.6% below sector average
Key checks
Key Insights
- Myriad Genetics, Inc.'s shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of -16.0%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 47.5% year-over-year.
- Ranks #114 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $368.0M | -47.5% |
| FY2024 | $701.1M | -10.5% |
| FY2023 | $783.2M | -11.6% |
| FY2022 | $885.8M | -8.5% |
| FY2021 | $967.8M | +9.9% |
| FY2020 | $881.0M | -19.1% |
| FY2019 | $1.1B | +12.7% |
| FY2018 | $966.1M | +25.7% |
| FY2017 | $768.4M | +3.9% |
| FY2016 | $739.6M | +11.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026